for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Otsuka Holdings Co Ltd

4578.T

Latest Trade

4,732.00JPY

Change

-15.00(-0.32%)

Volume

1,448,900

Today's Range

4,711.00

 - 

4,770.00

52 Week Range

3,434.00

 - 

5,829.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4,747.00
Open
4,748.00
Volume
1,448,900
3M AVG Volume
24.61
Today's High
4,770.00
Today's Low
4,711.00
52 Week High
5,829.00
52 Week Low
3,434.00
Shares Out (MIL)
542.27
Market Cap (MIL)
2,639,678.00
Forward P/E
20.74
Dividend (Yield %)
2.11

Next Event

Q3 2019 Otsuka Holdings Co Ltd Earnings Release

Latest Developments

More

Astex & Otsuka Announce Results Of Phase 3 Ascertain Study Of Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination

FDA Approves Taiho Oncology's Lonsurf For Adult Patients With Previously Treated Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma

Health Canada Approves Otsuka & Lundbeck's REXULTI As Adjunctive Treatment Of Major Depressive Disorder

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Otsuka Holdings Co Ltd

Otsuka Holdings Co., Ltd. is a Japan-based company engaged in medical, nutraceuticals related, consumer related and other business segments. The Company operates through four business segments. The Medical-related segment is engaged in the sale of ethical drugs, the manufacture, sale and export of curative medicines, as well as the research and development of infusions. The Nutraceuticals-related segment is engaged in the manufacture, purchase and sale of nutraceuticals-related products, such as functional foods and dietary supplements. The Consumer-related segment is engaged in the manufacture and sale of consumer products and mineral water. The Others segment is engaged in the manufacture and sale of chemical products, the manufacture, sale and import of measuring equipment, the manufacture of packaging products, the manufacture of synthetic resin molding products, as well as the storage and handling of its products.

Industry

Major Drugs

Contact Info

2-9, Kandatsukasa-machi

+81.3.67171410

https://www.otsuka.com/jp/

Executive Leadership

Ichiro Ohtsuka

Chairman of the Board, Chairman of Subsidiary, Representative Director

Tatsuo Higuchi

President, Chief Executive Officer, President of Subsidiary, Representative Director

Yuko Makino

Chief Financial Officer, Director

Masayuki Kobayashi

Chairman & President of Subsidiaries, Director

Atsumasa Makise

President of Subsidiary, Director

Key Stats

2.36 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2016

1.2K

2017

1.2K

2018

1.3K

2019(E)

1.4K
EPS (JPY)

2016

170.820

2017

207.600

2018

152.240

2019(E)

228.189
Price To Earnings (TTM)
30.45
Price To Sales (TTM)
1.96
Price To Book (MRQ)
1.49
Price To Cash Flow (TTM)
16.87
Total Debt To Equity (MRQ)
19.29
LT Debt To Equity (MRQ)
14.65
Return on Investment (TTM)
4.29
Return on Equity (TTM)
3.52

Latest News

BRIEF-Otsuka Pharmaceutical Says Co, X-Chem Have Signed Collaborative Research Agreement To Advance Discovery Process For New Otsuka Drug Compounds

* OTSUKA PHARMACEUTICAL SAYS CO, X-CHEM INC HAVE SIGNED COLLABORATIVE RESEARCH AGREEMENT TO ADVANCE DISCOVERY PROCESS FOR NEW OTSUKA DRUG COMPOUNDS Source text for Eikon: Further company coverage:

BRIEF-Otsuka Holdings to transfer medical device business to unit

* Says co plans to transfer medical device business to co's wholly owned unit Otsuka Medical Devices Co Ltd, with effective date of Jan. 1, 2018

BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

* FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults Source text for Eikon: Further company coverage:

BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type

* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018

BRIEF-Otsuka and Lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with bipolar I disorder

* unit Otsuka Pharmaceutical Co., Ltd. and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder

BRIEF-Otsuka Holdings, Lundbeck initiate two phase 3 trials of Brexpiprazole

* Otsuka and lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with Bipolar I disorder Source text for Eikon: Further company coverage:

BRIEF-Otsuka Holdings unit raises stake in India-based JV to 80 pct

* Says co's wholly owned unit Otsuka Pharmaceutical Factory, Inc raises stake in JV Otsuka Pharmaceutical India Private Limited to 80 percent

BRIEF-Otsuka Holdings unit acquires Canada-based firm

* Says co's wholly owned unit Otsuka Pharmaceutical Co., Ltd. acquires Canada-based firm, which is mainly engaged in development, manufacture and sales of plant-based foods

BRIEF-Otsuka Holdings unit says ABILIFY MAINTENA® for extended-release injectable suspension approved by U.S. FDA

* Says unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced ABILIFY MAINTENA®(aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and drug administration for the maintenance monotherapy treatment of bipolar I disorder (BP-I...

BRIEF-R&I affirms Otsuka Holdings's rating at "AA-" and changes outlook to stable from negative

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-"-R&I

BRIEF-Otsuka Holdings to spend about 7 bln yen on new equipment for cancer drug production - Nikkei

* Otsuka Holdings to spend about 7 billion yen on new equipment that produces active ingredients in cancer drugs - Nikkei Source (http://s.nikkei.com/2qAfD2u) Further company coverage:

BRIEF-Otsuka announces results of phase 3 data on tolvaptan

* Says primary and key secondary endpoints were positive for tolvaptan versus placebo in an additional phase 3 clinical trial

BRIEF- Otsuka Holdings unit to buy 20 pct voting power in India JV

* Says its wholly owned unit Otsuka Pharmaceutical Factory, Inc will buy 20 percent voting power in joint venture Otsuka Pharmaceutical India Private Limited (previous name Claris Otsuka Private Limited)

Akebia in marketing deal for anemia drug with Japan's Otsuka

Akebia Therapeutics Inc said it signed a co-development and marketing deal worth up to $1 billion for its experimental anemia drug with Japan's Otsuka Holdings Co Ltd.

BRIEF-Otsuka Holdings to adopt International Financial Reporting Standards

* Says the co to apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japanese Accounting Standards

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up